inclusion criteria: * lives in a household with an index case where the index case is a person with documented covid-19 (laboratory-confirmed sars-cov-2 infection with symptoms case) and must have 1) a first detectable sars-cov-2 test result from a sample collected within ≤5 days prior to randomization of the participant, and 2) at least 1 symptom attributable to covid-19 (e.g., fever, difficulty breathing) * does not have confirmed or suspected covid-19 * is willing and able to take oral medication * for males, agrees to be abstinent from penile-vaginal intercourse or agrees to use a highly effective contraceptive method while receiving study drug and for ≥3 months after the last dose of study drug * is female and not pregnant/breastfeeding and at least one of the following applies during the study and for ≥4 days after: is not a woman of childbearing potential (wocbp), is a wocbp and uses highly effective contraception (low user dependency method or a user dependent hormonal method in combination with a barrier method), or is a wocbp who is abstinent from heterosexual intercourse

inclusion criteria: * lives in a household with an index case where the index case is a person with documented covid-19 (laboratory-confirmed sars-cov-2 infection with symptoms case) and must have 1) a first detectable sars-cov-2 test result from a sample collected within ≤5 days prior to randomization of the participant, and 2) at least 1 symptom attributable to covid-19 (e.g., fever, difficulty breathing) * does not have confirmed or suspected covid-19 * is willing and able to take oral medication * for males, agrees to be abstinent from penile-vaginal intercourse or agrees to use a highly effective contraceptive method while receiving study drug and for ≥3 months after the last dose of study drug * is female and not pregnant/breastfeeding and at least one of the following applies during the study and for ≥4 days after: is not a woman of childbearing potential (wocbp), is a wocbp and uses highly effective contraception (low user dependency method or a user dependent hormonal method in combination with a barrier method), or is a wocbp who is abstinent from heterosexual intercourse

inclusion criteria: lives in a household with an index case where the index case is a person with documented covid-19 (laboratory-confirmed sars-cov-2 infection with symptoms case) and must have 1) a first detectable sars-cov-2 test result from a sample collected within ≤5 days prior to randomization of the participant, and 2) at least 1 symptom attributable to covid-19 (e.g., fever, difficulty breathing) does not have confirmed or suspected covid-19 is willing and able to take oral medication for males, agrees to be abstinent from penile-vaginal intercourse or agrees to use a highly effective contraceptive method while receiving study drug and for ≥3 months after the last dose of study drug is female and not pregnant/breastfeeding and at least one of the following applies during the study and for ≥4 days after: is not a woman of childbearing potential (wocbp), is a wocbp and uses highly effective contraception (low user dependency method or a user dependent hormonal method in combination with a barrier method), or is a wocbp who is abstinent from heterosexual intercourse

inclusion criteria: lives in a household with an index case where the index case is a person with documented covid-19 (laboratory-confirmed sars-cov-2 infection with symptoms case) and must have 1) a first detectable sars-cov-2 test result from a sample collected within ≤5 days prior to randomization of the participant, and 2) at least 1 symptom attributable to covid-19 (e.g., fever, difficulty breathing) does not have confirmed or suspected covid-19 is willing and able to take oral medication for males, agrees to be abstinent from penile-vaginal intercourse or agrees to use a highly effective contraceptive method while receiving study drug and for ≥3 months after the last dose of study drug is female and not pregnant/breastfeeding and at least one of the following applies during the study and for ≥4 days after: is not a woman of childbearing potential (wocbp), is a wocbp and uses highly effective contraception (low user dependency method or a user dependent hormonal method in combination with a barrier method), or is a wocbp who is abstinent from heterosexual intercourse

inclusion criteria: lives in a household with an index case where the index case is a person with documented covid-19 (laboratory-confirmed sars-cov-2 infection with symptoms case) and must have 1) a first detectable sars-cov-2 test result from a sample collected within ≤5 days prior to randomization of the participant, and 2) at least 1 symptom attributable to covid-19 (e.g., fever, difficulty breathing) does not have confirmed or suspected covid-19 is willing and able to take oral medication for males, there are no contraception requirements but must agree to follow local labelling (or local ethics or regulatory authority requirements) regarding contraception. is female and not pregnant/breastfeeding and at least one of the following applies during the study and for ≥4 days after: is not a woman of childbearing potential (wocbp), is a wocbp and uses highly effective contraception (low user dependency method or a user dependent hormonal method in combination with a barrier method), or is a wocbp who is abstinent from heterosexual intercourse

inclusion criteria: lives in a household with an index case where the index case is a person with documented covid-19 (laboratory-confirmed sars-cov-2 infection with symptoms case) and must have 1) a first detectable sars-cov-2 test result from a sample collected within ≤5 days prior to randomization of the participant, and 2) at least 1 symptom attributable to covid-19 (e.g., fever, difficulty breathing) does not have confirmed or suspected covid-19 is willing and able to take oral medication for males, there are no contraception requirements but must agree to follow local labelling (or local ethics or regulatory authority requirements) regarding contraception. is female and not pregnant/breastfeeding and at least one of the following applies during the study and for ≥4 days after: is not a woman of childbearing potential (wocbp), is a wocbp and uses highly effective contraception (low user dependency method or a user dependent hormonal method in combination with a barrier method), or is a wocbp who is abstinent from heterosexual intercourse

inclusion criteria: - lives in a household with an index case where the index case is a person with documented covid-19 (laboratory-confirmed sars-cov-2 infection with symptoms case) and must have 1) a first positive sars-cov-2 test result from a sample collected within ≤5 days prior to randomization of the participant, and 2) at least 1 symptom attributable to covid-19 (e.g., fever, difficulty breathing) - does not have confirmed or suspected covid-19 - is willing and able to take oral medication - is male and willing to be abstinent from heterosexual intercourse or use acceptable contraception during the study and for ≥4 days after the last dose of study intervention - is female and not pregnant/breastfeeding and at least one of the following applies during the study and for ≥4 days after: is not a woman of childbearing potential (wocbp), is a wocbp and uses highly effective contraception (low user dependency method or a user dependent hormonal method in combination with a barrier method), or is a wocbp who is abstinent from heterosexual intercourse

inclusion criteria: - lives in a household with an index case where the index case is a person with documented covid-19 (laboratory-confirmed sars-cov-2 infection with symptoms case) and must have 1) a first positive sars-cov-2 test result from a sample collected within ≤5 days prior to randomization of the participant, and 2) at least 1 symptom attributable to covid-19 (e.g., fever, difficulty breathing) - does not have confirmed or suspected covid-19 - is willing and able to take oral medication - is male and willing to be abstinent from heterosexual intercourse or use acceptable contraception during the study and for ≥4 days after the last dose of study intervention - is female and not pregnant/breastfeeding and at least one of the following applies during the study and for ≥4 days after: is not a woman of childbearing potential (wocbp), is a wocbp and uses highly effective contraception (low user dependency method or a user dependent hormonal method in combination with a barrier method), or is a wocbp who is abstinent from heterosexual intercourse

inclusion criteria: - lives in a household with an index case where the index case is a person with documented covid-19 (laboratory-confirmed sars-cov-2 infection with symptoms case) and must have 1) a first positive sars-cov-2 test result from a sample collected within 72 hours prior to randomization of the participant, and 2) at least 1 symptom attributable to covid-19 (e.g., fever, difficulty breathing) - does not have confirmed or suspected covid-19 - is willing and able to take oral medication - is male and willing to be abstinent from heterosexual intercourse or use acceptable contraception during the study and for ≥4 days after the last dose of study intervention - is female and not pregnant/breastfeeding and at least one of the following applies during the study and for ≥4 days after: is not a woman of childbearing potential (wocbp), is a wocbp and uses highly effective contraception, or is a wocbp who is abstinent from heterosexual intercourse

inclusion criteria: - lives in a household with an index case where the index case is a person with documented covid-19 (laboratory-confirmed sars-cov-2 infection with symptoms case) and must have 1) a first positive sars-cov-2 test result from a sample collected within 72 hours prior to randomization of the participant, and 2) at least 1 symptom attributable to covid-19 (e.g., fever, difficulty breathing) - does not have confirmed or suspected covid-19 - is willing and able to take oral medication - is male and willing to be abstinent from heterosexual intercourse or use acceptable contraception during the study and for ≥4 days after the last dose of study intervention - is female and not pregnant/breastfeeding and at least one of the following applies during the study and for ≥4 days after: is not a woman of childbearing potential (wocbp), is a wocbp and uses highly effective contraception, or is a wocbp who is abstinent from heterosexual intercourse